Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578


Delayed Quote. Delayed  - 08/26 05:35:10 pm
69.35 EUR   +1.14%
08/25 DÉPAKINE : 14 300 femmes enceintes seront indemnisées
08/24 SANOFI : Haiti Impact Trip Provides Eye-Opening Experience for Stop ..
08/22 MEDIVATION : Pfizer propose 14 milliards de dollars pour racheter Me..
News SummaryMost relevantAll newsSector news 

Sanofi's Genzyme Says MS Drug Lemtrada Shows More Trial Success

share with twitter share with LinkedIn share with facebook
share via e-mail
04/24/2012 | 09:39pm CEST

Genzyme, the U.S. biotechnology unit of France's Sanofi SA (SNY), Tuesday said latest results from a late-stage clinical study showed its multiple sclerosis drug Lemtrada significantly reduced relapses and any worsening of the condition, and in some cases showed a reversal in disability.

In a Phase III trial called CARE-MS II involving 840 patients, the relapse rate was reduced by 49%, compared with an older drug called Rebif, or subcutaneous interferon beta-1a, which is sold by German rival Merck KGaA (>> Merck KGaA).

The company said 65% of patients treated with Lemtrada were relapse-free after two years into the study, compared with 47% treated with Rebif.

Genzyme is developing the drug, also known as alemtuzumab, in collaboration with German drug maker Bayer AG (>> Bayer AG), and Sanofi aims to launch the drug by the end of next year. Multiple sclerosis is a chronic disease that attacks the central nervous system.

"We believe these ground-breaking results from CARE-MS II, including reversal of disability accumulation in some patients, achieved over the standard therapy Rebif, provide a message of hope for people living with MS," said David Meeker, Genzyme's CEO, said in a statement, adding: "We are on track to submit alemtuzumab for review to U.S. and EU regulatory authorities in the second quarter of this year."

In the CARE-MS II trial, alemtuzumab was given as an injection eight times over the course of the two-year study. The first treatment course of alemtuzumab was administered on five consecutive days, and the second course was administered on three consecutive days 12 months later. Rebif was administered by injection three times per week, each week, throughout the two years of study.

Sanofi, which is struggling with patent expiries on its blockbuster drugs, bought Genzyme in February 2011 in a bid to widen its research net.

--By Sten Stovall, Dow Jones Newswires; +44 207 842 9292; sten.stovall@dowjones.com

Stocks mentioned in the article : Merck KGaA, Bayer AG
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on SANOFI
08/25 SANOFI : Researchers from Sanofi Aventis Report Findings in Hepatic Encephalopat..
08/25 DÉPAKINE : 14 300 femmes enceintes seront indemnisées
08/24 SANOFI : Haiti Impact Trip Provides Eye-Opening Experience for Stop Hunger Now P..
08/22 MEDIVATION : Pfizer propose 14 milliards de dollars pour racheter Medivation
08/22 Pfizer to buy cancer drugmaker Medivation for $14 billion
08/22 Pfizer to buy Medivation and boost cancer drug portfolio
08/22 SANOFI : Provides Update on New Drug Application for Investigational Once-Daily ..
08/22DJPfizer Near $14 Billion Deal for Biotech -- WSJ
08/21 SANOFI : Research center in Oro Valley looks to grow after spinoff from Sanofi
More news
Sector news : Pharmaceuticals - NEC
08/27 Stada shareholder AOC pushes through board reshuffle
08/27 ABBOTT LABORATORIES : Whiplashed investors stay skittish about St. Jude
08/26DJST JUDE MEDICAL : . Jude Denies Claims in Muddy Waters Report
08/26DJALERE : Sues Abbott to Force Merger -- 2nd Update
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
08/26 FDA recommends Zika screening of blood components in all states and territori..
08/26 Updating My Price Target On Pfizer
08/26 What's Going On At Mylan?
08/26 Don't Fear The Fed - Cramer's Mad Money (8/25/16)
08/25 Shocked! Mylan, Biotechs Swoon After Hillary's Statement
Financials (€)
Sales 2016 36 960 M
EBIT 2016 9 286 M
Net income 2016 5 309 M
Debt 2016 5 008 M
Yield 2016 4,25%
P/E ratio 2016 15,83
P/E ratio 2017 14,42
EV / Sales 2016 2,55x
EV / Sales 2017 2,55x
Capitalization 89 393 M
More Financials
Duration : Period :
Sanofi Technical Analysis Chart | SAN | FR0000120578 | 4-Traders
Full-screen chart
Technical analysis trends SANOFI
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus HOLD
Number of Analysts 23
Average target price 84,5 €
Spread / Average Target 22%
Consensus details
EPS Revisions
More Estimates Revisions
Olivier Brandicourt Chief Executive Officer & Director
Serge Weinberg Chairman
JÚr˘me Contamine Chief Financial Officer & EVP-Finance
Elias E. Zerhouni President-Global Research & Development
Yong-Jun Liu Head-Global Research & Development
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI-11.77%100 075
JOHNSON & JOHNSON15.89%325 679
ROCHE HOLDING LTD.-11.47%214 671
PFIZER INC.7.87%211 206
NOVARTIS AG-9.62%210 234
More Results